ATR vs. DGX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ATR and DGX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
DGX’s market capitalization of 19.75 billion USD is significantly greater than ATR’s 10.64 billion USD, highlighting its more substantial market valuation.
With betas of 0.59 for ATR and 0.49 for DGX, both stocks show similar sensitivity to overall market movements.
| Symbol | ATR | DGX |
|---|---|---|
| Company Name | AptarGroup, Inc. | Quest Diagnostics Incorporated |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Instruments & Supplies | Medical - Diagnostics & Research |
| CEO | Stephan B. Tanda | James E. Davis |
| Price | 161.04 USD | 176.92 USD |
| Market Cap | 10.64 billion USD | 19.75 billion USD |
| Beta | 0.59 | 0.49 |
| Exchange | NYSE | NYSE |
| IPO Date | April 23, 1993 | December 17, 1996 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ATR and DGX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ATR
14.87%
Medical - Instruments & Supplies Industry
- Max
- 26.65%
- Q3
- 13.00%
- Median
- 1.08%
- Q1
- -8.11%
- Min
- -38.20%
In the upper quartile for the Medical - Instruments & Supplies industry, ATR’s Return on Equity of 14.87% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
DGX
13.22%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
DGX’s Return on Equity of 13.22% is on par with the norm for the Medical - Diagnostics & Research industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
ATR
11.90%
Medical - Instruments & Supplies Industry
- Max
- 20.14%
- Q3
- 7.36%
- Median
- 1.97%
- Q1
- -6.22%
- Min
- -20.00%
In the upper quartile for the Medical - Instruments & Supplies industry, ATR’s Return on Invested Capital of 11.90% signifies a highly effective use of its capital to generate profits when compared to its peers.
DGX
7.51%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
DGX’s Return on Invested Capital of 7.51% is in line with the norm for the Medical - Diagnostics & Research industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
ATR
10.42%
Medical - Instruments & Supplies Industry
- Max
- 28.95%
- Q3
- 11.24%
- Median
- -2.83%
- Q1
- -12.85%
- Min
- -26.41%
ATR’s Net Profit Margin of 10.42% is aligned with the median group of its peers in the Medical - Instruments & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
DGX
8.83%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
DGX’s Net Profit Margin of 8.83% is aligned with the median group of its peers in the Medical - Diagnostics & Research industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
ATR
14.17%
Medical - Instruments & Supplies Industry
- Max
- 32.10%
- Q3
- 16.03%
- Median
- 2.28%
- Q1
- -7.96%
- Min
- -26.84%
ATR’s Operating Profit Margin of 14.17% is around the midpoint for the Medical - Instruments & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
DGX
13.85%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
DGX’s Operating Profit Margin of 13.85% is around the midpoint for the Medical - Diagnostics & Research industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ATR | DGX |
|---|---|---|
| Return on Equity (TTM) | 14.87% | 13.22% |
| Return on Assets (TTM) | 8.18% | 5.68% |
| Return on Invested Capital (TTM) | 11.90% | 7.51% |
| Net Profit Margin (TTM) | 10.42% | 8.83% |
| Operating Profit Margin (TTM) | 14.17% | 13.85% |
| Gross Profit Margin (TTM) | 36.41% | 32.57% |
Financial Strength
Current Ratio
ATR
1.25
Medical - Instruments & Supplies Industry
- Max
- 6.79
- Q3
- 4.57
- Median
- 2.64
- Q1
- 1.81
- Min
- 1.10
ATR’s Current Ratio of 1.25 falls into the lower quartile for the Medical - Instruments & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
DGX
1.44
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
DGX’s Current Ratio of 1.44 aligns with the median group of the Medical - Diagnostics & Research industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ATR
0.41
Medical - Instruments & Supplies Industry
- Max
- 1.46
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.16
- Min
- 0.03
ATR’s Debt-to-Equity Ratio of 0.41 is typical for the Medical - Instruments & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
DGX
0.95
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
DGX’s leverage is in the upper quartile of the Medical - Diagnostics & Research industry, with a Debt-to-Equity Ratio of 0.95. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio
ATR
11.17
Medical - Instruments & Supplies Industry
- Max
- 25.04
- Q3
- 8.80
- Median
- 3.66
- Q1
- -3.85
- Min
- -11.93
ATR’s Interest Coverage Ratio of 11.17 is in the upper quartile for the Medical - Instruments & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
DGX
5.65
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
DGX’s Interest Coverage Ratio of 5.65 is in the upper quartile for the Medical - Diagnostics & Research industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | ATR | DGX |
|---|---|---|
| Current Ratio (TTM) | 1.25 | 1.44 |
| Quick Ratio (TTM) | 0.85 | 1.31 |
| Debt-to-Equity Ratio (TTM) | 0.41 | 0.95 |
| Debt-to-Asset Ratio (TTM) | 0.23 | 0.42 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.19 | 3.27 |
| Interest Coverage Ratio (TTM) | 11.17 | 5.65 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ATR and DGX. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ATR
1.12%
Medical - Instruments & Supplies Industry
- Max
- 4.02%
- Q3
- 0.38%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 1.12%, ATR offers a more attractive income stream than most of its peers in the Medical - Instruments & Supplies industry, signaling a strong commitment to shareholder returns.
DGX
1.72%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 1.72%, DGX offers a more attractive income stream than most of its peers in the Medical - Diagnostics & Research industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
ATR
31.58%
Medical - Instruments & Supplies Industry
- Max
- 76.77%
- Q3
- 11.37%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ATR’s Dividend Payout Ratio of 31.58% is in the upper quartile for the Medical - Instruments & Supplies industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
DGX
37.46%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DGX’s Dividend Payout Ratio of 37.46% is in the upper quartile for the Medical - Diagnostics & Research industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | ATR | DGX |
|---|---|---|
| Dividend Yield (TTM) | 1.12% | 1.72% |
| Dividend Payout Ratio (TTM) | 31.58% | 37.46% |
Valuation
Price-to-Earnings Ratio
ATR
28.83
Medical - Instruments & Supplies Industry
- Max
- 45.65
- Q3
- 44.10
- Median
- 35.47
- Q1
- 29.60
- Min
- 21.65
In the lower quartile for the Medical - Instruments & Supplies industry, ATR’s P/E Ratio of 28.83 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
DGX
21.89
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
In the lower quartile for the Medical - Diagnostics & Research industry, DGX’s P/E Ratio of 21.89 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Forward P/E to Growth Ratio
ATR
2.54
Medical - Instruments & Supplies Industry
- Max
- 5.80
- Q3
- 3.68
- Median
- 2.56
- Q1
- 1.87
- Min
- 0.22
ATR’s Forward PEG Ratio of 2.54 is within the middle range of its peers in the Medical - Instruments & Supplies industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
DGX
2.56
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
DGX’s Forward PEG Ratio of 2.56 is within the middle range of its peers in the Medical - Diagnostics & Research industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
ATR
2.99
Medical - Instruments & Supplies Industry
- Max
- 12.87
- Q3
- 6.95
- Median
- 3.45
- Q1
- 2.24
- Min
- 0.71
ATR’s P/S Ratio of 2.99 aligns with the market consensus for the Medical - Instruments & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
DGX
1.94
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
In the lower quartile for the Medical - Diagnostics & Research industry, DGX’s P/S Ratio of 1.94 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio
ATR
4.18
Medical - Instruments & Supplies Industry
- Max
- 9.60
- Q3
- 5.48
- Median
- 3.37
- Q1
- 1.95
- Min
- 0.65
ATR’s P/B Ratio of 4.18 is within the conventional range for the Medical - Instruments & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
DGX
2.83
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
Valuation at a Glance
| Symbol | ATR | DGX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 28.83 | 21.89 |
| Forward PEG Ratio (TTM) | 2.54 | 2.56 |
| Price-to-Sales Ratio (P/S, TTM) | 2.99 | 1.94 |
| Price-to-Book Ratio (P/B, TTM) | 4.18 | 2.83 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 29.67 | 18.70 |
| EV-to-EBITDA (TTM) | 14.80 | 13.39 |
| EV-to-Sales (TTM) | 3.25 | 2.57 |